# F2G

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/f2g

- Industry: Biotechnology
- Headquarters: Manchester, UK
- Website: www.f2g.com
- Total disclosed funding: $107M
- Latest round: Series H (Sep 12, 2024)
- Investors on record: 12

## About

F2G Ltd., based in the UK, is a biotechnology company focused on developing innovative therapeutics for rare and life-threatening fungal infections, addressing significant healthcare challenges with advanced antifungal agents.Founded in 1998, F2G Ltd. specializes in therapeutics for fungal infections. The company, headquartered in Manchester, UK, has been actively involved in funding rounds, having recently raised USD 100 mn in Series H funding on September 12, 2024. The funding led by AMR Action Fund included contributions from numerous investors, facilitating their ongoing development efforts. The founder’s history is not specified, and there are no known subsidiaries or significant business pivots to report.F2G Ltd specializes in the development of novel therapeutics aimed at treating rare and life-threatening fungal infections. Their core product offerings focus on innovative antifungal agents designed to address the challenges posed by resistant fungal pathogens. These therapeutics leverage cutting-edge scientific advancements to offer patients more treatment options, particularly in cases where traditional antifungal therapies fall short. F2G’s products are primarily targeted at healthcare providers, hospitals, and specialty pharmacies within the UK and select European markets, ensuring that patients facing critical fungal infections receive timely and effective care. The company's commitment to a patient-first ethos drives its research and development efforts as they strive to expand the therapeutic landscape for this underserved patient population.In the most recent year, F2G reported revenue of USD 0 mn with an EBITDA of USD -55.53 mn. The company generates revenue through strategic partnerships and collaborations with healthcare institutions, pharmaceutical companies, and specialty distributors, focusing on B2B transactions that facilitate access to their antifungal products for healthcare providers and patients in critical need.F2G Ltd. plans to utilize the recent Series H funding of USD 100 mn to finalize late-stage development and prepare for the regulatory approval of olorofim, which is slated for commercialization in the US. The company aims to expand its market presence, specifically targeting new geographic regions in Europe and North America by 2025, enhancing access to its antifungal therapeutics for more patients in need. Their strategic focus will continue to align with their commitment to addressing rare fungal infections.

## Funding rounds

- Series H, Sep 12, 2024, $100M — Intermediate Capital Group, Sofinnova Partners, Merifin Capital, Novo Holdings, Forbion, Brace Pharma Capital, Advent Life Sciences, Morningside, AMR Action Fund, Blue Owl
- Series A, Aug 16, 2002, $6.8M — BankInvest, Dunhaw Capital

## Investors

- BankInvest (https://capitalatlas.ai/funds/bankinvest) — Series A
- Dunhaw Capital — Series A
- Intermediate Capital Group — Series H
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series H
- Merifin Capital (https://capitalatlas.ai/funds/merifin-capital) — Series H
- Novo Holdings — Series H
- Forbion (https://capitalatlas.ai/funds/forbion) — Series H
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series H
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series H
- Morningside (https://capitalatlas.ai/funds/morningside) — Series H
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series H
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series H